An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
-
- Tun Kiat Ko
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Asif Javed
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Kian Leong Lee
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Thushangi N. Pathiraja
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Xingliang Liu
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Simeen Malik
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Sheila Xinxuan Soh
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Xiu Ting Heng
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Naoto Takahashi
- Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan;
-
- Joanna H. J. Tan
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Ravi Bhatia
- Division of Hematology-Oncology, Department of Medicine, University of Alabama Birmingham, Birmingham, AL;
-
- Alexis J. Khng
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Wee-Joo Chng
- Department of Hematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore;
-
- Yee Yen Sia
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- David A. Fruman
- Department of Molecular Biology & Biochemistry, University of California, Irvine, CA;
-
- King Pan Ng
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Zhu En Chan
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Kim Jiajing Xie
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Qiangze Hoi
- Computational and Systems Biology, Genome Institute of Singapore, Singapore;
-
- Cheryl Xueli Chan
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Audrey S. M. Teo
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- Oscar Velazquez Camacho
- Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany;
-
- Wee Yang Meah
- Human Genetics, Genome Institute of Singapore, Singapore;
-
- Chiea Chuen Khor
- Human Genetics, Genome Institute of Singapore, Singapore;
-
- Chin Thing J. Ong
- Next Generation Sequencing Platform, Genome Institute of Singapore, Singapore;
-
- Wei Jia W. Soon
- Next Generation Sequencing Platform, Genome Institute of Singapore, Singapore;
-
- Patrick Tan
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
-
- Pauline C. Ng
- Computational and Systems Biology, Genome Institute of Singapore, Singapore;
-
- Charles Chuah
- Department of Haematology, Singapore General Hospital, Singapore;
-
- Axel M. Hillmer
- Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;
-
- S. Tiong Ong
- Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;
説明
<jats:title>Abstract</jats:title> <jats:p>Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) CML remains challenging because BC cells acquire complex molecular alterations that confer stemness features to progenitor populations and resistance to BCR-ABL1 tyrosine kinase inhibitors. Comprehensive models of BC transformation have proved elusive because of the rarity and genetic heterogeneity of BC, but are important for developing biomarkers predicting BC progression and effective therapies. To better understand BC, we performed an integrated multiomics analysis of 74 CP and BC samples using whole-genome and exome sequencing, transcriptome and methylome profiling, and chromatin immunoprecipitation followed by high-throughput sequencing. Employing pathway-based analysis, we found the BC genome was significantly enriched for mutations affecting components of the polycomb repressive complex (PRC) pathway. While transcriptomically, BC progenitors were enriched and depleted for PRC1- and PRC2-related gene sets respectively. By integrating our data sets, we determined that BC progenitors undergo PRC-driven epigenetic reprogramming toward a convergent transcriptomic state. Specifically, PRC2 directs BC DNA hypermethylation, which in turn silences key genes involved in myeloid differentiation and tumor suppressor function via so-called epigenetic switching, whereas PRC1 represses an overlapping and distinct set of genes, including novel BC tumor suppressors. On the basis of these observations, we developed an integrated model of BC that facilitated the identification of combinatorial therapies capable of reversing BC reprogramming (decitabine+PRC1 inhibitors), novel PRC-silenced tumor suppressor genes (NR4A2), and gene expression signatures predictive of disease progression and drug resistance in CP.</jats:p>
収録刊行物
-
- Blood
-
Blood 135 (26), 2337-2353, 2020-06-25
American Society of Hematology